FLT3 ligand plasma levels in acute myeloid leukemia

Haematologica. 2019 Jun;104(6):e240-e243. doi: 10.3324/haematol.2018.209460. Epub 2019 Jan 10.

Authors

Pierre Peterlin^{1

2}, Joelle Gaschet², Thierry Guillaume^{3

2}, Alice Garnier³, Marion Eveillard^{2

4}, Amandine Le Bourgeois³, Michel Cherel^{2

5}, Camille Debord⁴, Yannick Le Bris^{2

4}, Olivier Theisen⁴, Béatrice Mahé³, Viviane Dubruille³, Catherine Godon⁴, Nelly Robillard⁴, Soraya Wuilleme⁴, Cyrille Touzeau³, Thomas Gastinne³, Nicolas Blin³, Anne Lok³, Antoine Bonnet³, Steven Le Gouill^{3

2}, Philippe Moreau^{3

2}, Marie-C Béné^{2

4}, Patrice Chevallier^{3

2}

Affiliations

¹ Hematology Clinic, CHU Nantes pierre.peterlin@chu-nantes.fr.
² CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes.
³ Hematology Clinic, CHU Nantes.
⁴ Hematology Biology, CHU, Nantes.
⁵ Nuclear Medicine Unit, ICO Cancer Center Gauducheau, Saint Herblain, France.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers
Disease Management
Humans
Induction Chemotherapy
Kaplan-Meier Estimate
Leukemia, Myeloid, Acute / blood*
Leukemia, Myeloid, Acute / diagnosis*
Leukemia, Myeloid, Acute / mortality
Leukemia, Myeloid, Acute / therapy
Membrane Proteins / blood*
Prognosis
Proportional Hazards Models
Time Factors

Substances

Biomarkers
Membrane Proteins
flt3 ligand protein